GSK Menveo Vaccine Gets EU CHMP Green Light
Ticker: GLAXF · Form: 6-K · Filed: Sep 24, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 24, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, vaccine, pharmaceuticals
TL;DR
GSK's Menveo vaccine just got a big thumbs up from EU regulators for a new liquid version. Big win for the company.
AI Summary
On September 24, 2024, GSK plc announced that its Menveo meningococcal vaccine received a positive opinion from the European CHMP for a new single-vial, fully liquid presentation. This positive opinion is a significant step towards potential approval by the European Commission, which would allow GSK to market the vaccine in this new format across the EU.
Why It Matters
This positive opinion could lead to a more convenient and accessible version of the Menveo vaccine for European patients, potentially boosting GSK's vaccine portfolio.
Risk Assessment
Risk Level: low — The filing is an announcement of a positive regulatory opinion, which is generally good news and does not introduce new risks.
Key Players & Entities
- GSK plc (company) — Registrant and developer of the vaccine
- Menveo (product) — Meningococcal vaccine
- European CHMP (company) — Committee for Medicinal Products for Human Use, regulatory body
- European Commission (company) — Potential final approver of the vaccine
- September 24, 2024 (date) — Date of the announcement
FAQ
What is the significance of the positive CHMP opinion for GSK's Menveo vaccine?
The positive opinion from the European CHMP is a crucial step towards potential approval by the European Commission for the new single-vial, fully liquid presentation of the Menveo vaccine.
What is the new presentation of the Menveo vaccine that received the positive opinion?
The new presentation is a single-vial, fully liquid formulation of the Menveo meningococcal vaccine.
Which regulatory body issued the positive opinion?
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued the positive opinion.
What is the next step after the CHMP's positive opinion?
The next step is for the European Commission to review the CHMP's opinion and make a final decision on the approval of the new vaccine presentation.
When was this announcement made?
The announcement was issued on September 24, 2024.
Filing Stats: 1,250 words · 5 min read · ~4 pages · Grade level 12.5 · Accepted 2024-09-24 06:10:14
Filing Documents
- a2998f.htm (6-K) — 48KB
- 0001654954-24-012186.txt ( ) — 49KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: September 24, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc